Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_provenance.
- NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_provenance.
- NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_assertion evidence source_evidence_literature NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_provenance.
- NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_assertion SIO_000772 15814649 NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_provenance.
- NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_assertion wasDerivedFrom befree-2016 NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_provenance.
- NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_assertion wasGeneratedBy ECO_0000203 NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_provenance.
- befree-2016 importedOn "2016-02-19" NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_provenance.